RxDoctor Payments Data

Daniel Klein, DO

Gastroenterology · Weston, FLNPI 1629518279

Payments from drug & device makers

$1,553in general payments, 2019–2025

Across 73 payments — averaging $21.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$450
  • Ardelyx, Inc.$201
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$185
  • Takeda Pharmaceuticals U.S.A., Inc.$146
  • Johnson & Johnson$145
  • Shire North American Group Inc$123
  • plus $301 from 8 others

What the payments were for

  • Speaking & faculty fees$1258%
  • Food & beverage$1,42892%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,553 in reported general payments places this provider in the 30th percentile of 1,388 gastroenterology providers in Florida.

See all gastroenterology providers in Florida

Medicare billing

Part B allowed, 2024
$63,332
Medicare patients
278
Services billed
524

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab11$353,434
ZenpepLipase/Protease/Amylase13$24,669
LinzessLinaclotide23$18,377
MotegrityPrucalopride Succinate18$11,352
Omeprazole127$1,595
CholestyramineCholestyramine (With Sugar)13$947
Esomeprazole Magnesium44$822
Colestipol Hcl13$766
Pantoprazole Sodium55$746
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl34$528
Lactulose13$366
Famotidine27$287
Mirtazapine13$177
Metronidazole15$168
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl12$157

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$145$353,43411 claims
Aimmune Therapeutics, Inc.Zenpep$24$24,66913 claims
AbbVieLinzess$450$18,37723 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$146$11,35218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 1,388 gastroenterology providers in Florida.

Other gastroenterology in Weston

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →